FIRMAGON POWDER FOR SOLUTION

Country: Կանադա

language: անգլերեն

source: Health Canada

active_ingredient:

DEGARELIX (DEGARELIX ACETATE)

MAH:

FERRING INC

ATC_code:

L02BX02

INN:

DEGARELIX

dosage:

80MG

pharmaceutical_form:

POWDER FOR SOLUTION

composition:

DEGARELIX (DEGARELIX ACETATE) 80MG

administration_route:

SUBCUTANEOUS

units_in_package:

80MG

prescription_type:

Prescription

therapeutic_area:

ANTINEOPLASTIC AGENTS

leaflet_short:

Active ingredient group (AIG) number: 0152667001; AHFS:

authorization_status:

APPROVED

authorization_date:

2009-11-16

SPC

_Pr_
_FIRMAGON_
_®_
_ _
_Page 1 of 46 _
PRODUCT MONOGRAPH
Pr
FIRMAGON
®
Degarelix for Injection
120 mg degarelix (as degarelix acetate) per vial
80 mg degarelix (as degarelix acetate) per vial
Gonadotropin-Releasing Hormone Receptor Antagonist
Ferring Pharmaceuticals
200 Yorkland Blvd., Suite 500
North York, Ontario
M2J 5C1
DATE OF REVISION:
March 18, 2016
SUBMISSION CONTROL NO: 180927
_Pr_
_FIRMAGON_
_®_
_ _
_Page 2 of 46 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................8
DRUG INTERACTIONS
..................................................................................................11
DOSAGE AND ADMINISTRATION
..............................................................................12
OVERDOSAGE
................................................................................................................26
ACTION AND CLINICAL PHARMACOLOGY
............................................................26
STORAGE AND STABILITY
..........................................................................................30
SPECIAL HANDLING INSTRUCTIONS
.......................................................................30
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................30
PART II: SCIENTIFIC INFORMATION
...............................................................................31
PHARMACEUTICAL INFORMATION
............................................